InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone49-36-4150-8180
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date4/4/2019 (Estimated)
OptionableNot Optionable
Inflarx (NASDAQ:IFRX) Frequently Asked Questions
What is Inflarx's stock symbol?
Inflarx trades on the NASDAQ under the ticker symbol "IFRX."
How were Inflarx's earnings last quarter?
Inflarx NV (NASDAQ:IFRX) released its quarterly earnings data on Thursday, August, 9th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.24. View Inflarx's Earnings History.
When is Inflarx's next earnings date?
What price target have analysts set for IFRX?
8 brokers have issued 1 year price targets for Inflarx's stock. Their predictions range from $42.00 to $65.00. On average, they expect Inflarx's share price to reach $53.1250 in the next twelve months. This suggests a possible upside of 15.1% from the stock's current price. View Analyst Price Targets for Inflarx.
What is the consensus analysts' recommendation for Inflarx?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inflarx in the last year. There are currently 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inflarx.
Has Inflarx been receiving favorable news coverage?
News articles about IFRX stock have trended somewhat positive recently, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Inflarx earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the near future.
Who are some of Inflarx's key competitors?
Some companies that are related to Inflarx include Amneal Pharmaceuticals (AMRX), Taro Pharmaceutical Industries (TARO), TESARO (TSRO), ACADIA Pharmaceuticals (ACAD), HUTCHISON CHINA/S (HCM), Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), Evotec (EVTCY), Ultragenyx Pharmaceutical (RARE), Intercept Pharmaceuticals (ICPT), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT), Reata Pharmaceuticals (RETA), Akcea Therapeutics (AKCA) and Mirati Therapeutics (MRTX).
What other stocks do shareholders of Inflarx own?
Who are Inflarx's key executives?
Inflarx's management team includes the folowing people:
- Dr. Niels C. Riedemann M.D., Ph.D., Co-Founder, CEO & Exec. Director (Age 47)
- Prof. Renfeng Guo, Co-Founder, Chief Scientific Officer & Exec. Director (Age 49)
- Mr. Arnd Christ, Chief Financial Officer (Age 53)
- Mr. Jason M. Marks, Chief Legal Officer, Gen. Counsel & Corp. Sec.
- Mr. Jordan Silverstein, Head of Corp. Devel. & Strategy
When did Inflarx IPO?
(IFRX) raised $100 million in an initial public offering (IPO) on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.
Who are Inflarx's major shareholders?
Inflarx's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include RA Capital Management LLC (8.91%), BlackRock Inc. (5.39%), Polar Capital LLP (0.61%), Emory University (0.35%), Millennium Management LLC (0.31%) and Essex Investment Management Co. LLC (0.09%).
Which institutional investors are selling Inflarx stock?
IFRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Geode Capital Management LLC, Northern Trust Corp, Emory University and D. E. Shaw & Co. Inc..
Which institutional investors are buying Inflarx stock?
IFRX stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Polar Capital LLP, Essex Investment Management Co. LLC, Bank of America Corp DE, Paloma Partners Management Co and Millennium Management LLC.
How do I buy shares of Inflarx?
Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inflarx's stock price today?
One share of IFRX stock can currently be purchased for approximately $46.16.
How big of a company is Inflarx?
Inflarx has a market capitalization of $1.08 billion. The company earns $-27,390,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis.
What is Inflarx's official website?
How can I contact Inflarx?
Inflarx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 49-36-4150-8180.
MarketBeat Community Rating for Inflarx (NASDAQ IFRX)
MarketBeat's community ratings are surveys of what our community members think about Inflarx and other stocks. Vote "Outperform" if you believe IFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IFRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
